Approval for Diabetes and Weight Management Over the past decade, three GLP-1/GIP receptor agonists liraglutide, semaglutide, and tirzepatide initially approved by the FDA for adults with type 2 diabetes, have also gained FDA approval for chronic weight management in people without diabetes, provided they meet specific criteria: a BMI of 30, or 27 with at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes
Regenerative Support: Research suggests GHK-Cu plays a vital role in signaling tissue remodeling and skin vitality
R.ShanmugasundaramE
Thomsen RW, Mailhac A, Lohde JB, Pottegard A
Our medically-supervised weight-loss program is designed to make the process comfortable and worry-free for you, with access to our medical staff should you have any questions or concerns